NAD-boosting treatment shows no Parkinson's benefit in yearlong trial
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Novel radiotherapy may save increasingly many rectal cancer patients from surgery and a stoma
United Kingdom
-
Maternal vaccines protect babies from serious infections, but unequal access limits benefits across Europe
United Kingdom
-
Scientists identify the neuroblastoma cells that signal poor outcomes
United Kingdom
-
'Immune fog' may flag lung cancer risk years before tumor develops
United Kingdom
-
Peanut consumption affects the lipid profile circulating in the blood
United Kingdom
-
Abdominal fluid reveals rare immune cells that may limit attacks on tumors
United Kingdom
-
Electrical ablation boosts CAR-NK cell therapy against liver cancer, offering new strategy for refractory solid tumors
United Kingdom
-
A self-disinfecting fabric eliminates bacteria, fungi and viruses in hospital settings
United Kingdom